Menu
12/01/2004
Deodorant sprays linked to breast tumour growth: study
Chemicals commonly found in antiperspirants could be linked to the growth of breast tumours, according to new research published in the Journal of Applied Toxicology.
The University of Reading research team found that parabens, chemicals found in underarm cosmetics and other products, can be detected in human breast tumours. Parabens are typically used as preservatives in thousands of cosmetic, food and pharmaceutical products.
Although the connection has yet to be proven, the team says that the research "represents an important link that will be crucial to further investigations".
Researchers studied samples of 20 different human breast tumours, which revealed a higher than average concentration of parabens in the tumour tissue. The team believes that the most likely reason for their accumulation in the affected area was direct application to the skin - probably through paraben-laced deoderant spray.
Dr Philippa Darbre, lead author of the study, said: "Their detection in human breast tumours is of concern since parabens have been shown to be able to mimic the action of the female hormone oestrogen and oestrogen can drive the growth of human breast tumours. It would therefore seem especially prudent to consider whether parabens should continue to be used in such a wide range of cosmetics applied to the breast area (including antiperspirants/deodorants)."
(gmcg)
The University of Reading research team found that parabens, chemicals found in underarm cosmetics and other products, can be detected in human breast tumours. Parabens are typically used as preservatives in thousands of cosmetic, food and pharmaceutical products.
Although the connection has yet to be proven, the team says that the research "represents an important link that will be crucial to further investigations".
Researchers studied samples of 20 different human breast tumours, which revealed a higher than average concentration of parabens in the tumour tissue. The team believes that the most likely reason for their accumulation in the affected area was direct application to the skin - probably through paraben-laced deoderant spray.
Dr Philippa Darbre, lead author of the study, said: "Their detection in human breast tumours is of concern since parabens have been shown to be able to mimic the action of the female hormone oestrogen and oestrogen can drive the growth of human breast tumours. It would therefore seem especially prudent to consider whether parabens should continue to be used in such a wide range of cosmetics applied to the breast area (including antiperspirants/deodorants)."
(gmcg)
Related UK National News Stories
Click here for the latest headlines.
12 April 2006
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
Breast cancer patient wins Herceptin court battle
A breast cancer patient has won an appeal to receive the drug Herceptin on the NHS. Ann Marie Rogers, 54, from Swindon went to the Court of Appeal after the High Court ruled that Swindon Primary Care Trust had not acted unlawfully in refusing to give her the drug.
15 February 2006
Woman loses Herceptin treatment case
A woman being treated for breast cancer has lost a court battle to get the anti-cancer drug Herceptin prescribed on the NHS.
Woman loses Herceptin treatment case
A woman being treated for breast cancer has lost a court battle to get the anti-cancer drug Herceptin prescribed on the NHS.
08 August 2014
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
27 June 2014
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
Blood Test Could Predict Breast Cancer - Research
A blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, according to research by the University College London (UCL).
23 April 2014
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay. The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.
-
Northern Ireland WeatherToday:A cloudy day with a little light rain or drizzle at times, but some spells of drier weather too. The north coast may become somewhat brighter later this afternoon. Maximum temperature 11 °C.Tonight:Cloudy and patchy light rain will slowly clear away this evening. Then the rest of the night will be dry with broken cloud. Westerly winds freshening in the early hours. Minimum temperature 6 °C.
